Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.

MacDonald DA, Martin J, Muthusamy KK, Luo JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, Bono F, Delesque N, Savi P, Francis J, Amirkhosravi A, Meyer T, Romano C, Glinka M, Yancopoulos GD, Stahl N, Wiegand SJ, Papadopoulos N.

Angiogenesis. 2016 Jul;19(3):389-406. doi: 10.1007/s10456-016-9515-8. Epub 2016 May 27.

2.

Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.

Yang J, Wang X, Fuh G, Yu L, Wakshull E, Khosraviani M, Day ES, Demeule B, Liu J, Shire SJ, Ferrara N, Yadav S.

Mol Pharm. 2014 Oct 6;11(10):3421-30. doi: 10.1021/mp500160v. Epub 2014 Sep 16.

PMID:
25162961
3.

Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.

Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ.

Ophthalmology. 2017 Mar;124(3):352-358. doi: 10.1016/j.ophtha.2016.10.036. Epub 2016 Nov 24.

PMID:
27890437
4.

PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.

Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M, Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T.

Retina. 2017 Jan;37(1):179-190. doi: 10.1097/IAE.0000000000001117.

PMID:
28005721
5.

Potential anti-vascular endothelial growth factor therapies for central retinal vein occlusion.

Figueroa MS, Contreras I.

Drugs. 2012 Nov 12;72(16):2063-71. doi: 10.2165/11640820-000000000-00000.

PMID:
23061805
6.

Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept.

Walker A, Chung CW, Neu M, Burman M, Batuwangala T, Jones G, Tang CM, Steward M, Mullin M, Tournier N, Lewis A, Korczynska J, Chung V, Catchpole I.

J Biol Chem. 2016 Mar 11;291(11):5500-11. doi: 10.1074/jbc.M115.691162. Epub 2016 Jan 4.

7.

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.

Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel.

JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.

PMID:
26512939
8.

Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.

Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA.

Br J Ophthalmol. 2015 Feb;99(2):141-6. doi: 10.1136/bjophthalmol-2014-305149. Epub 2014 Jun 11. Review.

PMID:
25271911
9.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

10.

Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J; SCORE2 Investigator Group.

JAMA. 2017 May 23;317(20):2072-2087. doi: 10.1001/jama.2017.4568.

11.

Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.

Ranjbar M, Brinkmann MP, Zapf D, Miura Y, Rudolf M, Grisanti S.

Cell Physiol Biochem. 2016;38(2):737-47. doi: 10.1159/000443030. Epub 2016 Feb 15.

12.

Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.

Pfau M, Fassnacht-Riederle H, Becker MD, Graf N, Michels S.

Ophthalmic Res. 2015;54(3):150-6. doi: 10.1159/000439223. Epub 2015 Sep 29.

PMID:
26413794
13.

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network.

Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27.

14.

A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.

Li Y, Busoy JM, Zaman BAA, Tan QSW, Tan GSW, Barathi VA, Cheung N, Wei JJ, Hunziker W, Hong W, Wong TY, Cheung CMG.

Exp Eye Res. 2018 Sep;174:98-106. doi: 10.1016/j.exer.2018.05.027. Epub 2018 May 28.

PMID:
29852133
15.

Aflibercept: an update on recent milestones achieved.

Palejwala NV, Lauer AK.

Drugs Today (Barc). 2014 Dec;50(12):779-90. doi: 10.1358/dot.2014.50.12.2245587. Review.

PMID:
25588083
16.

Bevacizumab and Aflibercept Activate Platelets via FcγRIIa.

Nomura Y, Kaneko M, Miyata K, Yatomi Y, Yanagi Y.

Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8075-82. doi: 10.1167/iovs.15-17814.

PMID:
26720459
17.

[Management of aflibercept in routine clinical practice].

Cabrera López F.

Arch Soc Esp Oftalmol. 2015 Mar;90 Suppl 1:29-34. doi: 10.1016/S0365-6691(15)30007-1. Review. Spanish.

PMID:
25925049
18.

Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.

Klettner A, Recber M, Roider J.

Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1593-8. doi: 10.1007/s00417-014-2719-y. Epub 2014 Jul 22.

PMID:
25047874
19.

The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.

Elshout M, van der Reis MI, Webers CA, Schouten JS.

Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):1911-20. doi: 10.1007/s00417-014-2641-3. Epub 2014 Apr 29.

PMID:
24777708
20.

Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy.

Kanda A, Noda K, Saito W, Ishida S.

Sci Rep. 2015 Dec 9;5:17946. doi: 10.1038/srep17946.

Supplemental Content

Support Center